193 related articles for article (PubMed ID: 7911160)
1. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Kunitoh H; Watanabe K; Onoshi T; Furuse K; Niitani H; Taguchi T
J Clin Oncol; 1996 May; 14(5):1649-55. PubMed ID: 8622084
[TBL] [Abstract][Full Text] [Related]
4. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Fossella FV; Lee JS; Berille J; Hong WK
Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Robinet G; Thomas P; Pérol M; Vergnenègre A; Lena H; Taytard A; Paillotin D; Bessa EH; Schuller-Lebeau MP
Rev Mal Respir; 2000 Feb; 17(1):83-9. PubMed ID: 10756559
[TBL] [Abstract][Full Text] [Related]
10. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel for previously treated non-small-cell lung cancer.
Fossella FV
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
15. Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
Mukohara T; Takeda K; Miyazaki M; Takifuji N; Terakawa K; Negoro S
Cancer Chemother Pharmacol; 2001 Nov; 48(5):356-60. PubMed ID: 11761452
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Miller VA; Rigas JR; Francis PA; Grant SC; Pisters KM; Venkatraman ES; Woolley K; Heelan RT; Kris MG
Cancer; 1995 Feb; 75(4):968-72. PubMed ID: 7842417
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Gandara DR; Edelman MJ; Lau D
Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
[TBL] [Abstract][Full Text] [Related]
19. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
20. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
